L-DOX

প্রাপ্তবয়স্ক:

Dosage Ovarian Cancer Patients: The recommended dose is 50 mg/m2 intravenously over 60 minutes every 28 days until disease progression or unacceptable toxicity.AIDS-Related Kaposi’s Sarcoma: The recommended dose is 20 mg/m2 intravenously over 60 minutes every 21 days until disease progression or unacceptable toxicity.Multiple Myeloma: The recommended dose is 30 mg/m2 intravenously over 60 minutes on day 4 of each 21-day cycle for eight cycles or until disease progression or unacceptable toxicity. Administer it after Bortezomib on day 4 of each cycle.Dose Modification: Guidelines have been proposed since Doxorubicin Hydrochloride Liposome injectionexhibits nonlinear pharmacokinetics at 50 mg/m2. Dose adjustments may thus result in non-proportional greater change in plasma concentration and exposure to the drug. Patients should be carefully monitored for toxicity. Adverse events such as Palmar Plantar Erythema (PPE), hematologic toxicities, and stomatitis may be managed by dose delays and adjustments. Subsequent to the first appearance of a Grade 2 or higher adverse event, dosing should be adjusted and or delayed as described in the following tables and should not be increased at any given time.Pediatric Use: The safety and effectiveness of Doxorubicin Hydrochloride Liposome injection in pediatric patients have not been established.